Comparative Pharmacology
Head-to-head clinical analysis: FURADANTIN versus UREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURADANTIN versus UREX.
FURADANTIN vs UREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit bacterial enzymes involved in cell wall synthesis, DNA replication, and RNA transcription. It is bactericidal against susceptible organisms.
Urex (methenamine hippurate) is hydrolyzed in acidic urine to formaldehyde and ammonia. Formaldehyde denatures bacterial proteins and nucleic acids, exerting a nonspecific bactericidal effect. The hippuric acid component maintains urinary acidity.
100 mg orally twice daily for 5-7 days; acute uncomplicated cystitis: 50 mg four times daily or 100 mg twice daily for 5 days.
100 mg orally twice daily for 3 days (uncomplicated UTI) or 100 mg orally once daily for 5 days (prophylaxis).
None Documented
None Documented
Terminal elimination half-life is 0.3-1 hour in adults with normal renal function; prolonged to 1-4 hours in renal impairment (creatinine clearance <60 mL/min) and may exceed 20 hours in anuria.
Terminal elimination half-life is 14-18 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 40 hours in severe impairment), necessitating dose adjustment.
Renal: 36% (glomerular filtration and tubular secretion); fecal: 40-50% (biliary excretion and unabsorbed drug); hepatic metabolism: minor (acetylation and reduction) accounting for <10%.
Primarily renal: approximately 60-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination accounts for <5%.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective